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The eﬀects of 12-week exposure to zidovudine (AZT) at 400, 500, and 600mg/kg/d were examined on expression of 542
mitochondria-related genes and mitochondrial DNA (mtDNA) copy number in the liver of male and female B6C3F1 mice to
understand mitochondrial role in sex-related diﬀerences in development of lactic acidosis. Plasma lactate levels and hematologic
parameters were also examined. Results indicated increased red blood cell (RBC) count in vehicle-treated controls, whereas a
dose-related decline in the RBC count was noted in AZT-treated mice compared to the basal levels before treatments began. These
decreases were associated with signiﬁcant dose-related increases in mean corpuscular volume and mean corpuscular hemoglobin
levels. This eﬀect was greater in AZT-treated females compared to males. In both sexes, 12-week AZT or vehicle exposure
signiﬁcantly reduced plasma lactate levels compared to the basal levels. Results also showed modest, but signiﬁcant, changes in the
expression of genes associated with apoptosis and lipid metabolism at 600mg/kg/d AZT. Neither drug nor sex inﬂuenced hepatic
mtDNA copy number. Altogether, 12-week AZT exposure as high as 600mg/kg/d did not impair hepatic mitochondria or induce
lacticacidosisinB6C3F1 mice.However, AZT-mediatedhematologictoxicityappeared tobegreaterinfemalescompared tomales.
1.Introduction
The use of nucleoside reverse transcriptase inhibitors
(NRTIs) in treatment of HIV-1 infections has been associat-
ed with a wide range of severe side eﬀects, including lac-
tic acidosis, hepatotoxicity, pancreatitis, lipodystrophy, neu-
ropathy, and hematotoxicity [1]. In addition, sex-related dif-
ferences in the frequency and severity of NRTI-related ad-
verseeﬀectshavebeenreported.Ithasbeenshownthatwom-
en are less likely than men to tolerate NRTI therapy [2]
and also are at higher risk for developing NRTI-related tox-
icities [3]. Possible risk factors for sex-related diﬀerences in
NRTI-induced toxicities include diﬀerences in body mass
index,sexhormones,activitiesofkinases,drug-metabolizing
enzymes, and the transport and excretion of the drug [4, 5].
Nonetheless, the molecular basis for an increased risk of
developing NRTI-inducedtoxicity inHIV-1-infectedwomen
still remains unclear.
The majority of NRTI-related complications are believed
to be due to altered mitochondrial function caused by phos-
phorylated metabolites of NRTIs that can inhibit DNA poly-
merase gamma and/or result in mtDNA chain termination
[6, 7]. DNA polymerase gamma is the mitochondria-speciﬁc
polymeraserequiredforreplicationandrepairofthemtDNA
that encodes critical proteins for energy production by oxi-
dativephosphorylation.InhibitionofDNApolymerasegam-
ma and/or damage to mtDNA by NRTIs would alter ener-
gy production, consequently impairing cellular and mito-
chondrial function. Inhibition of DNA polymerase gamma
by NRTIs leading to the depletion of mtDNA levels has been2 AIDS Research and Treatment
reported [8, 9]. Several studies, however, have also shown
that NRTIs, such as zidovudine(AZT), can impair mito-
chondrial function independent of its eﬀect on DNA poly-
merase gamma. This drug can aﬀect other cellular targets
including proteins involved in mitochondrial bioenergetics
[10, 11], various metabolic pathways, and mitochondrial
membrane transporters [12, 13].
One of the established measures of impaired mitochon-
drial energy production is higher blood lactate levels, which
ultimately could lead to a life-threatening condition called
lactic acidosis. Although rare, lactic acidosis is considered
one of the most serious complications of NRTI therapy. It
poses a major health concern in HIV-1-infected women,
especially pregnant women, who are at greater risk of devel-
oping this adverse event compared to men [14, 15]. Thus,
there is evidence that mitochondrial dysfunction is involved
in NRTI-mediated side eﬀects. However, the association bet-
ween altered mitochondrial function and sex-based diﬀer-
ences in NRTI-induced adverse events, in particular, lactic
acidosis, has not been established.
Bearing in mind that higher plasma lactate levels have
been associated with mitochondrial dysfunction and that
sex-related diﬀerences exist in the respiratory/oxidative po-
tential of hepatic mitochondria [16], understanding mito-
chondrial activity during NRTI exposure will be critical
to gain important insights into the role of mitochondria
in sex-related diﬀerences in the development of hyperlac-
tataemia/lactic acidosis. To address this, we examined the ex-
pression levels of 542 mitochondria-related genes and rela-
tive mtDNA copy number in the liver of male and female
B6C3F1 mice treated with AZT, a principal antiretroviral
drug used in combination regimens to treat HIV-1 infection.
PlasmalactatelevelsweremeasuredduringAZTtreatmentto
determine possible hyperlactataemia. Based on clinical stud-
ies that demonstrate AZT-related hematologic toxicity [17,
18], the RBC count, hemoglobin(Hb), mean corpuscular
volume (MCV), and mean corpuscular hemoglobin (MCH)
levels were also measured during AZT treatments in these
mice.
2.MaterialsandMethods
2.1. Animal Husbandry. Male and female B6C3F1 mice were
obtained from the breeding colony at the National Cen-
ter for Toxicological Research(NCTR). Mice were raised
in a pathogen-free environment and treated according to
Institutional Animal Care and Use Committee guidelines.
Animals were housed two per polycarbonate cage with hard-
wood chip bedding and maintained at 23◦Cw i t har e l a t i v e
humidity of 50%. The animals were conditioned to a 12 hr
light/12 hr dark cycle with lights on from 0600 to 1800hr
daily and were given autoclaved NIH-31 diet and ﬁltered tap
water ad libitum.
2.2. Animal Treatments. Beginning at 8 weeks of age, mice
were administered AZT(Cipla, Mumbai, India) by gavage at
0, 400, 500, and 600mg/kg body weight/day for 12 weeks.
McTween, which is a mixture of 0.2% methylcellulose and
0.1% polysorbate 80, was used as the vehicle. The AZT
doses of 400, 500, and 600mg/kg/d were selected based
on a prior study that showed altered expression levels of
hepatic mitochondria-related genes at 240mg/kg AZT in
C3B6F1 trp53 transgenic mice [13]. Also, the AZT doses of
the current study were selected to severely impair mitochon-
drial function, but not high enough to be fatal to the ani-
mal. The human therapeutic dose for AZT is 10mg/kg body
weight/day [19]. On the basis of body surface area (mg/m2),
the mice on the current study were exposed to 3.2, 4.0, and
4.8 times the clinical therapeutic dose, respectively. Control
mice were administered McTween by gavage. Each group
consisted of six animals. Animals were weighed and moni-
tored daily for abnormal clinical signs.
2.3. Tissue Collection. Blood was collected from mice before
treatment began and also during the course of the treatment.
Blood was collected from the saphenous vein of each animal
and a portion of the blood was transferred into Microtainer
tubescontainingsodiumﬂuorideandpotassiumoxalate(BD
Biosciences, Franklin Lakes, NJ) for the measurements of
lactate levels. The remaining blood was transferred into
Microtainer tubes containing EDTA(BD Biosciences) for the
measurements of hematologic parameters(RBC count, Hb,
MCV, MCH). Blood samples collected for lactate measure-
ments were immediately centrifuged at 1000×g for 10 min-
utes at room temperature to separate the plasma. Following
12-week treatment, animals were humanely euthanized by
excessive inhalation of gaseous CO2 24 hr after the last dose.
To avoid possible adverse eﬀects of CO2 asphyxiation on
lactate levels, 30 minutes prior to euthanization, blood was
collected from the saphenous vein for lactate measurements.
Immediately following euthanasia, the median lobe of the
liver was removed, minced in RNA later(Ambion, Austin,
TX) and stored at −20◦C until expression analysis of mito-
chondria-related genes. Another piece of the liver was imme-
diately frozen in liquid nitrogen and stored at −80◦C until
measurements of mtDNA copy number.
2.4. Measurement of Expression Levels of Mitochondria-Re-
l a t e dG e n e sU s i n gt h eM o u s eM i t o C h i p .Extraction of total
RNA from liver tissues, reverse transcription to cDNA and
labeling with ﬂuorescent cyanine dyes, hybridization of la-
beled cDNAs on MitoChips, washing and scanning of hy-
bridized arrays were as described previously [20]. In brief,
total RNA was isolated from liver tissues using Qiagen
RNeasy mini kit (Qiagen, Valencia, CA) followed by quan-
tiﬁcation of extracted RNA on a spectrophotometer at
260nm and 280nm. The quality of RNA samples was fur-
ther determined using the RNA 6000 LabChip and Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) and
RNA samples with RNA integration number higher than
8.5 were used for microarray experiment. DNase-treated
RNA samples were reverse transcribed using random hex-
amer primers (Invitrogen, Carlsbad, CA) and SuperScript II
reverse transcriptase (Invitrogen) in the presence of reverse
transcription labeling mixture containing dNTPs (Invitro-
gen)andaminoallyl-dUTP(aa-dUTP,Sigma,St.Louis,MO).AIDS Research and Treatment 3
Following puriﬁcation, the aminoallyl-cDNA pellet was cou-
pled with ﬂuorescent cyanine dyes (Cy3 or Cy5, Amersham
Pharmacia,Piscataway,NJ).StratageneUniversalMouseRef-
erence RNA(UMRR, Agilent Technologies, Cedar Creek,
TX) was used as a reference RNA. Experimental samples and
UMRR were labeled with Cy5 and Cy3, respectively. Each
Cy5-labeled sample was cohybridized with Cy3-labeled
UMRR on a MitoChip arrays and hybridized at 42◦Cf o r1 8
hours in a water bath. This was followed by washing of arrays
withsodiumchloridesodiumcitratebuﬀercontainingdiﬀer-
ent concentrations of sodium dodecyl sulphate prewarmed
at 30◦C. MitoChip arrays were printed at the National Cen-
ter for Toxicological Research. Each slide consisted of two
microarrays. Following hybridization, arrays were scanned
with a GenePix 4000B scanner(Axon Instruments, Union
City, CA) at 10μm resolution.
The expression level of each gene for a sample was esti-
mated by the average of the log2 ratio of the ﬂuorescence
of Cy5(the sample) relative to the ﬂuorescence of Cy3(the
reference) from the two arrays on the slide. Each array
consisted of 9 housekeeping genes as positive controls and 9
Arabidopsis genes as negative controls. The expression lev-
el of control genes(housekeeping genes and Arabidopsis
genes) for a sample was averaged and used as a covariate to
normalize the expression data. A relative fold-change in the
expression level of a gene was calculated as the ratio of the
average expression of treated samples to untreated con-
trols. Diﬀerences associated with treatment, sex, and their
interactions were estimated under a ﬁxed eﬀect linear mod-
el with adjustment for batch eﬀects and normalizing covar-
iates using the Generalized Linear Model procedure of SAS
9.1.3. The results were further classiﬁed into diﬀerent Gene
Ontologies using the database from Mouse Genome Infor-
matics (http://www.informatics.jax.org/). Overall treatment
eﬀects on the groups of genes (molecular function/biological
process) were tested using a modiﬁed meta-analysis method
for combining correlated P values [21].
2.5. Isolation of DNA and Measurement of Relative mtDNA
Copy Number in the Liver. Isolation of DNA and measure-
ment of relative mtDNA copy number in the liver were
as described previously [22]. In brief, approximately 20mg
of liver tissue was homogenized in phosphate buﬀered sa-
line (PBS) containing ΦX174 DNA(replicative form; NE
Biolabs, Beverly, MA) as a reference DNA. To this, RNace-
It(Agilent Technologies, Santa Clara, CA), and phosphory-
lase b from rabbit muscle(Sigma-Aldrich, St. Louis, MO)
were added, followed by the addition of PBS without phage
DNA to a ﬁnal volume of 500μL before incubation at
37◦C for 2 hours. This was followed by addition of 90μL
of a digestion buﬀer containing 180mM TRIS-HCl (pH
8.0), 60mM sodium EDTA, 10% SDS, and 1.2mg protein-
ase K (Qiagen, Valencia, CA) and tubes were incubated at
55◦C overnight. This digest was further incubated at 95◦C
for 15 minutes, cooled to room temperature, and brieﬂy cen-
trifuged. Isolation of DNA from the digest was performed
using TRI Reagent LS(Sigma-Aldrich) according to manu-
facturer’s instructions. The resulting DNA pellets were dis-
solved in 75μL of 8mM NaOH, and the quality and quantity
of the DNA was assessed with an ND-1000 spectrophotome-
ter(NanoDrop, Wilmington, DE).
RelativemtDNAcopynumberwasdeterminedbyamod-
iﬁcationofthequantitativereal-timePCR[TaqMan(Applied
Biosystems), Foster City, CA)] assay method developed by
Myers and colleagues [22]. Samples were analyzed on an
ABI 7500 Sequence Detection System(Applied Biosystems)
using TaqMan MGB probes designed for sequences speciﬁc
to a region of the mouse mtDNA D-loop and the ΦX174
DNA reference. A calibrator sample containing equal ratios
of D-loop and ΦX174 sequence was run on every plate used
for quantitative-PCR analysis to allow all of the samples
to be expressed as an n-fold diﬀerence relative to the cali-
brator using SDS software v1.1 (Applied Biosystems) and
the comparative Ct method [23]. Two-way ANOVA was per-
formed to determine AZT- and sex-related eﬀects on relative
mtDNA copy number.
2.6. Measurements of Plasma Lactate Level and Hematologi-
cal Parameters. L a c t a t em e a s u r e m e n t sw e r ec a r r i e do u tu s -
ing a lactate kit according to the manufacturer’s instructions
(Trinity Biotech, Ireland) on a COBAS Mira Plus automated
spectrophotometer (Roche, Nutley, NJ). Statistical signiﬁ-
canceofdose-relatedchangesinlactatelevelsforeachsexwas
tested under a ﬁxed eﬀects linear model with a covariate of
dose levels. Statistical signiﬁcance of sex-related diﬀerences
in lactate levels between 0- and 12-week was tested by t-
tests, and P-values less than 0.05 were considered signiﬁcant.
During the course of the treatments(0–11-week), the RBC
count, Hb content, MCV, and MCH were measured every
week on a hematology analyzer, the PENTRA 60 C+(Horiba
ABX, France), using ABX reagents to determine anemia. Sta-
tistical signiﬁcance of dose-related changes for each sex and
sex-related diﬀerences in hematological parameters between
0- and 11-week was evaluated by t-tests, and P values less
than 0.05 were considered signiﬁcant. For the estimation of
diﬀerences and the statistical analysis, a Generalized Linear
Model of SAS 9.1.3 was used.
3. Results and Discussion
The present study evaluated liver mitochondria in AZT-
treated B6C3F1 mice to understand the role of mitochondria
in sex-related diﬀerences in the development of lactic
acidosis. Both male and female B6C3F1 mice were treated
with 400, 500, or 600mg/kg/d AZT at doses predicted to
severely alter mitochondrial function leading to hyperlac-
tataemia/lactic acidosis. Despite the relatively high doses of
AZT, there was no increase in plasma lactate levels in these
mice. However, other classical parameters of clinical toxicity
observed with AZT were altered and in a sex-related manner.
During the course of AZT treatments, hematological
parameters were measured through 11 weeks of treatment to
monitor possible anemia in these mice. Following 11-week
exposure, signiﬁcant changes in hematological parameters
were found at all AZT exposures(Table 1). An AZT-related
decline in the RBC count was observed in both sexes. The4 AIDS Research and Treatment
decreases in the RBC counts were 13%, 11%, and 8% in
maleAZT-treatedmiceat400, 500, and600mg/kg/d, respec-
tively, whereas the decreases were between 16–26% in female
mice compared to 0-week(Table 1), and these declines were
signiﬁcant at 400 and 600mg/kg/d AZT only in female mice.
This may indicate a greater inﬂuence of AZT on the RBC
count in female mice than males and this sex-related dif-
ference was signiﬁcant at the 500mg/kg/d dose. The occur-
rence of anemia characterized by reduced Hb levels has
been reported in HIV-1 infected patients on NRTI therapies
[24, 25]. In the present study, however, the Hb contents were
not signiﬁcantly altered despite the decline in RBC counts at
allAZTdoses(Table 1).Ontheotherhand,smallincreasesin
RBCandHbcontentswereobservedinmaleandfemalemice
following 11-week vehicle treatment compared to 0-week,
and the increase was signiﬁcant only in RBC counts in male
mice(Table 1). At present, a likely mechanism underlying
signiﬁcant ﬁndings in vehicle-treated mice is unclear. More
experiments need to be conducted to evaluate these changes.
In addition to the decline in RBC counts, AZT-treated
mice showed signiﬁcant dose-related increases in MCV and
MCH levels(Table 1). Male mice treated with 400, 500, or
600mg/kg/d AZT had a 22%, 22%, or 29% increase, respec-
tively, in MCV at 11-week compared to 0-week. In AZT-
treated female mice, the MCV levels were increased by
29%, 29%, and 36% following 11-week treatment with
400, 500, and 600mg/kg/d AZT, respectively. In both AZT-
treated male and female mice, these changes in MCV were
associated with increases in MCH levels. While male mice
had 15%, 17%, and 22% increases in MCH at 400, 500,
and 600mg/kg/d AZT, respectively, female mice showed
19%, 20%, and 27% increases at 400, 500, and 600mg/kg/d
AZT, respectively. Thus, as for the RBC counts, a greater
AZT inﬂuence was seen in female mice, and this sex-related
diﬀerence was signiﬁcant at 400 and 500mg/kg/d doses for
bothMCVandMCHlev elsb u tnotat600mg/kg/d(Table 1).
It is possible that beyond a certain threshold high concentra-
tion of AZT may overcome the genomic diﬀerences between
sexes.
The MCV represents the average size of the RBC, and
MCH indicates the amount of Hb in each RBC. Dose-related
increases in MCV and MCH levels in AZT-treated mice
might suggest a compensatory mechanism in response to a
dose-related decline in the RBC count, which may further
explain nonsigniﬁcant changes observed in Hb contents in
these mice. Corroborating these ﬁndings are animal studies
that reported hematologic toxicity as evidenced by the
decreased erythrocyte count, higher MCV and MCH levels,
and increased incidence of macrocytic anemia during AZT
exposure [26–28]. The increased MCV indicates larger than
normal RBCs, which are known as macrocytes. Although Hb
levels were not altered in AZT-treated mice, higher MCV
and MCH levels in response to decreased RBC count may
indicate the initial phase of macrocytic anemia in these
mice. Interestingly, a sex eﬀect was seen in both MCV and
MCH levels, where AZT-treated female mice had greater
increases than their male counterparts and these increases
were signiﬁcant at 400 and 500mg/kg/d doses. Altogether,
these ﬁndings suggest the occurrence of hematotoxicity in
AZT-treated B6C3F1 mice at all doses and this toxicity ap-
peared to be greater in female mice than in males.
Although an increase in plasma lactate levels was antic-
ipated upon AZT exposure, 12-week dosing with AZT
signiﬁcantly reduced plasma lactate levels in both male
and female mice compared to the levels before treatment
began(Table 2). The decreases in lactate levels showed no
AZT dose response and were also found in animals treated
with vehicle alone. The mechanism(s) underlying these
decreasesinlactatelevelsisunclear.Controlandtreatedmice
were given McTween, which is a commonly used emulsifying
agent in drug treatments of laboratory animals in toxicology
studies. However, changes in lactate levels in vehicle-treated
mice similar to those seen in AZT-treated mice suggest a
likely inﬂuence of McTween on lactate levels rather than the
AZT. In future studies, the use of sterile water as the drug
vehicle may help avoid this possible confounding eﬀect.
In toxicological studies, increased lactate levels have
been related to mitochondrial dysfunction in various drug-
induced toxicities [29, 30]. In the present study, however,
none of the AZT doses signiﬁcantly altered the transcription
levels of genes involved in mitochondrial energy production
in the liver of B6C3F1 mice. In view of these ﬁndings, lack
of increase in plasma lactate levels in AZT-treated mice is
not surprising. A moderate, but signiﬁcant eﬀect of AZT
was evident only at 600mg/kg/d on the expression levels
of genes associated with apoptosis and lipid metabolism
(Table 3).Expressionlevelsofproapoptoticgenes(Bax,Bbc3,
and Bnip3) were signiﬁcantly increased in the liver. Bbc3
induces a conformational change in Bax, which is essential
for apoptotic events mediated through the intrinsic pathway
[31], whereas Bnip3 induces apoptosis by opening the
mitochondrial permeability pore with consequential mem-
brane depolarization [32]. Although immunohistochemical
evaluation was not performed in the liver tissues to verify
apoptotic changes, increased expression of proapoptotic
genes may indicate a cellular response to AZT exposure,
probably to remove damaged cells. Supporting this interpre-
tation are in vitro and in vivo studies that reported increased
apoptosis during exposures to antiretroviral drugs, including
AZT [33, 34].
AZT-treated mice also exhibited diﬀerential expression
of genes involved in lipid metabolism at 600mg/kg/d dose.
Increased transcriptional level of acyl-coenzyme A synthase
(Acsl3) was associated with decreased expression levels of
acyl-coenzyme A dehydrogenases for short-chain (Acads),
short/branched chain (Acadsb), and long-chain fatty acids
(Acadl). Acsl3 is required for the activation of long-chain
fatty acids, whereas Acads, Acadsb, and Acadl are involved
in the initial step of fatty acid β-oxidation. Decreases in
the expression levels of acyl-coenzyme A dehydrogenases in
AZT-treated mice were modest; however, in long-term ther-
apies, such changes may, in part, contribute to fat accumu-
lationintheliver.Hepaticsteatosis,aconditioncharacterized
by excess fat accumulation within liver cells, has been indi-
cated as one of the complications of antiretroviral therapy
in HIV-1 infected patients [35]. Overall, the eﬀect of AZT
on hepatic mitochondria was minimal in B6C3F1 mice. This
was further supported by nonsigniﬁcant changes in mtDNAAIDS Research and Treatment 5
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Table 2: Plasma lactate levels in B6C3F1 mice.
AZT dose(mg/kg/d)
Plasma lactate level(mg/dL)
0-week 12-week
Male Female Male Female
0 101.4 ±10.3 126.5 ±15.4 71.5±1.8a 62.0±3.2a,b
400 100.0 ±3.79 2 .6 ±9.2 79.3±8.0a 56.0±5.8a,b
500 96.7 ±3.28 7 .5 ±2.2 57.9±5.2a 56.3±4.2a
600 92.6 ±4.29 1 .2 ±2.6 65.7±4.3a 52.7±2.3a,b
aindicates a signiﬁcant (P<0.05) diﬀerence in plasma lactate levels at 12-week compared to 0-week for each sex.
bindicates a signiﬁcant (P<0.05) sex-related diﬀerence in plasma lactate levels in female mice compared to male counterparts at 12-week.
Values are presented as the mean ± SEM (N = 4).
Table 3: Eﬀect of AZT (600mg/kg/d) on the expression levels of genes in the liver of B6C3F1 mice.
Gene description (gene symbol) GenBank accession ID FC P
Apoptosis (18), P = 0.039
Bcl2-associated X protein (Bax)N M 007527 1.143 0.020
Bcl2 binding component 3 (Bbc3)N M 133234 1.065 0.032
Bcl2/adenovirus E1B 19 k Da-interacting protein 1, NIP3 (Bnip3)N M 009760 1.159 0.041
Lipid metabolism (23), P = 0.046
Acyl-Coenzyme A synthetase long-chain family member 3 (Acsl3) AK012088 1.166 0.001
Acyl-Coenzyme A dehydrogenase, long-chain (Acadl)N M 007381 −1.159 0.025
Acyl-Coenzyme A dehydrogenase, short-chain (Acads)N M 007383 −1.142 0.022
Acyl-Coenzyme A dehydrogenase, short/branched chain (Acadsb)N M 025826 −1.225 0.011
Mitochondrial genes (13),P = NS
NADH ubiquinone dehydrogenase, subunit 1 (mt-Nd1) AK018753 1.080 0.310
NADH ubiquinone dehydrogenase, subunit 2 (mt-Nd2) AU018363 1.080 0.280
NADH ubiquinone dehydrogenase, subunit 3 (mt-Nd3) J01420 1.021 0.724
NADH ubiquinone dehydrogenase, subunit 4 (mt-Nd4) AB042809 1.018 0.827
NADH ubiquinone dehydrogenase, subunit 4L (mt-Nd4l) AA109866 1.048 0.526
NADH ubiquinone dehydrogenase, subunit 5 (mt-Nd5) AU018713 1.050 0.564
NADH ubiquinone dehydrogenase, subunit 6 (mt-Nd6) AA435281 1.081 0.144
Cytochrome b (mt-Cytb) AU018811 1.013 0.861
Cytochrome c oxidase, subunit I (mt-Co1) AU018394 1.014 0.829
Cytochrome c oxidase, subunit II (mt-Co2) AU019143 1.054 0.449
Cytochrome c oxidase, subunit III (mt-Co3) AB042432 1.018 0.765
ATP synthase, subunit 6 (mt-ATP6) AF093677 1.008 0.906
ATP synthase, subunit 8 (mt-ATP8) J01420 1.067 0.464
The bold numbers in parentheses indicate number of genes evaluated for the molecular function. P values in bold represent eﬀect of AZT on the molecular
function, which is a combined eﬀect of AZT-related changes in expression levels of number of genes evaluated for the molecular function. FC indicates a
relativefoldchangeinmicetreatedwith600mg/kg/dAZTcomparedtovehicle-treatedcontrolmice.Negativevaluesoffoldchangesindicatedown-regulation
of genes. Mitochondrial genes important in energy production, for which 600mg/kg/d AZT did not alter transcription, are also presented in the table. Sex-
related diﬀerences in the expression levels of mitochondria-related genes were not observed in liver of AZT-treated mice. NS: Not signiﬁcant.
Table 4: Relative mitochondrial DNA (mtDNA) copy number in the livers of B6C3F1 mice.
AZT dose (mg/kg/d) B6C3F1 mice
Male Female
01 2 .02 ±4.87 (N = 6) 8.46 ±1.51 (N = 6)
400 8.46 ± 3.83 (N = 5) 7.37 ±1.57 (N = 6)
500 18.69 ±8.26 (N = 6) 8.95 ±1.29 (N = 6)
600 11.66 ±7.05 (N = 5) 10.08 ±1.75 (N = 5)
The mtDNA copy number was based on quantitative real-time PCR measurements of D-loop concentration relative to the concentration of ΦX174RF added
at a ﬁxed concentration before DNA extraction. The numbers in parentheses indicate the number of animals in the group. Values are presented as the mean
± SEM (Standard error of the mean).AIDS Research and Treatment 7
copy number in the livers of AZT-treated mice (Table 4).
Expression levels of mtDNA-encoded genes critical in ener-
gy production also remained unaltered by AZT treatment
(Table 3). In addition, AZT-treated mice did not show sex-
related diﬀerences in the expression levels of mitochondria-
related genes or mtDNA copy number in the liver. Sex-
based diﬀerences in the expression levels were evident only
in vehicle-treated controls: female mice showing higher
expression levels compared to males, and these genes were
associated with complexes I, III, and V of oxidative phospho-
rylation and the Krebs cycle (data not shown).
In contrast to the paucity of gene expression changes
found in this investigation, a previous study from our labo-
ratory using a diﬀerent mouse model showed that the ex-
pression of 164 genes was signiﬁcantly altered by AZT ex-
posure [13]. The reasons for this dramatic diﬀerence may
be attributed to diﬀerences in genotype, age, and exposure
to AZT. In the previous study, a p53 haplodeﬁcient mouse
strain was used. The single functional copy of the p53 gene
in this strain may allow cells with damaged mitochondria
to survive, and thus express altered mitochondria-encoding
genes, by partially inhibiting apoptosis. The ages of the mice
in the two studies, as well as the duration of exposure,
were also diﬀerent with young animals being used in the
prior study(exposed perinatally from gestation day 12 to 18
followed by continuation of same treatment from postnatal
day 1 through 28 days of age) and adult animals(exposed
f r o m8w e e k so fa g et o2 0w e e k so fa g e )u s e di nt h ep r e s e n t
study.Furtherstudieswillberequiredtofullyunderstandthe
possible inﬂuence of genotype and age on gene expression
changes induced by AZT.
In conclusion, the AZT doses used in the present study,
although as high as 600mg/kg/d, did not induce hyperlac-
tataemia/lactic acidosis in B6C3F1 mice. This could be due
to the absence of an AZT eﬀect on hepatic mitochondria as
evidenced by nonsigniﬁcant changes in the expression levels
ofmitochondria-relatedgenes:inparticular,genesassociated
with oxidative phosphorylation or the copy number of
mtDNA. It is possible that higher doses of AZT and/or long-
er duration of AZT exposure may be necessary to signif-
icantly impair hepatic mitochondrial function in order to
develop hyperlactataemia/lactic acidosis in B6C3F1 mice.
Alternatively, use of a more sensitive mouse model, such as
the p53 haplodeﬁcient mouse, may accelerate mitochondrial
dysfunction and will provide better insights into the role
of mitochondria in sex-associated diﬀerences in AZT-related
adverse events. In B6C3F1 mice, AZT eﬀect on mitochondria
was limited to modest changes in the expression levels of
genes associated with apoptosis and lipid metabolism and
occurred only at the highest dose. A striking ﬁnding, how-
e v e r ,w a sas e x - r e l a t e dd i ﬀerence in hematologic toxicity in
AZT-treated mice: female mice exhibiting a greater response
than males.
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